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http://dx.doi.org/10.1016/j.ccr.2012.11.014SUMMARYLoss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma
stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss
of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced
tumor incidence and leads to invasive cancer and lymph node metastasis. Whereas p53 controls DNA
damage and IEC survival during the initiation stage, loss of p53 during tumor progression is associated
with increased intestinal permeability, causing formation of an NF-kB-dependent inflammatory microenvi-
ronment and the induction of epithelial-mesenchymal transition. Thus, we propose a p53-controlled
tumor-suppressive function that is independent of its well-established role in cell-cycle regulation,
apoptosis, and senescence.INTRODUCTION
The development of invasive cancer is a multistep process
involving mutations in tumor-suppressor genes and proto-
oncogenes that are successively acquired over several decades
(Hahn and Weinberg, 2002). Such accumulation of genetic
alterations correlating with tumors ranging from benign
adenomas to invasive cancer was first proposed for colorectal
carcinogenesis (Vogelstein et al., 1988). Mutations in APC or
CTNNB1 are found in the majority of colorectal tumors, and
thus activation of the Wnt pathway has been suggested to serveSignificance
Wedemonstrate that p53 in intestinal epithelial cells confers tw
late-stage carcinogenesis. These results provide functional e
invasion and metastasis and unravel a function of this tumor s
ment. Furthermore, we establish a valuable mouse model of c
studies such as the preclinical assessment of potential therape
approaches.as a gatekeeper of colorectal tumor development (Fodde et al.,
2001). Other key proteins that are proposed to be affected at
different stages in this adenoma-to-carcinoma progression
model are K-RAS, SMAD4, DCC, and p53 (Fearon and Vogel-
stein, 1990). Among these, p53 is considered one of the most
important tumor suppressors for not only colorectal carcino-
genesis but also nearly all malignancies. Upon DNA damage
or oncogenic stress, wild-type p53 guards the genome and
maintains genomic stability by transcriptional regulating genes
involved in apoptosis, cell-cycle arrest, senescence, or DNA
repair (Riley et al., 2008). Therefore, loss of this essential tumoro different tumor-suppressivemechanisms during early- and
vidence for an essential role of p53 during colorectal tumor
uppressor in the creation of an inflammatory microenviron-
olorectal carcinogenesis that will be useful for translational
utic regimens or the longitudinal evaluation of in vivo imaging
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p53 Suppresses Colonic Tumor Progressionsuppressor provides a tumor cell with substantial growth advan-
tages. In the colorectal tumor progression model, loss of p53
tumor suppressor function has been suggested to occur at
the transition stage from late adenomas to invasive carcinoma
(Vogelstein et al., 1988). Although recent genetic studies have
confirmed that TP53 is one of the most commonly mutated
genes in human colorectal cancer (Wood et al., 2007), functional
evidence supporting an essential role for p53 to specifically
suppress colorectal tumor invasion is, however, still lacking.
Apart from the successive acquisition of mutations that
provide tumor cells with a cell-autonomous growth advantage,
an inflammatory tumor microenvironment represents another
prerequisite for all stages of tumor development (Grivennikov
et al., 2010) and has recently been included in the revised hall-
marks of cancer (Hanahan and Weinberg, 2011). Activation of
certain oncogenes initiates an intrinsic inflammatory response
that is characterized by the expression of tumor-promoting
chemokines and cytokines as well as the recruitment of innate
immune cells (Mantovani et al., 2008). This leads to the activation
of fibroblasts, matrix remodeling, angiogenesis, and the release
of soluble mediators that promote survival of initiated malignant
cells in a paracrine manner (Grivennikov et al., 2010). Further-
more, the existence of an inflammatory microenvironment is
considered to provide the basis for invasion and metastasis
(Joyce and Pollard, 2009). The two transcription factors NF-kB
and STAT3 comprise two central signaling pathways in the
inflammatory tumor microenvironment because they control
various protumorigenic processes such as growth, proliferation,
survival, angiogenesis, and invasion (Bollrath and Greten, 2009).
Moreover, in initiated neoplastic cells, they regulate the pro-
duction of chemokines that attract cytokine-secreting inflamma-
tory cells, which lead to further NF-kB and STAT3 activation in
tumor cells and therefore participate in a positive feedforward
loop that sustains tumor-associated inflammation (Grivennikov
et al., 2010).
Here, we aimed to examine the intestinal epithelial cell (IEC)-
specific tumor-suppressive function of p53 and the potential
involvement of NF-kB during tumor progression.
RESULTS
Loss of Tp53 in IECs Is Not Sufficient to Initiate Intestinal
Neoplasia
To specifically examine the functional role of p53 in IEC homeo-
stasis as well as during intestinal tumor development, we
crossed villin-Cre mice (Madison et al., 2002) to Tp53F/F mice
(Jonkers et al., 2001). The resulting mice lacking exons 2–10 of
Tp53 in their IECs, termed Tp53DIEC, developed normally and
were healthy and fertile. IEC-specific loss of Tp53 did not disturb
the frequency of intestinal stem cells or intestinal differentiation
(see Figures S1A–S1G available online), and importantly had no
effect on baseline proliferation or apoptosis of unchallenged
mice (Figures S1H and S1I). Consequently, loss of p53 did not
provide a growth advantage in ex-vivo-induced crypt organoid
formation (Figure S1J) and did not lead to spontaneous intestinal
tumor formation when mice were monitored up to 14 months
(n = 20). In order to test the effect of IEC-restricted p53 loss in
a Wnt-driven model of intestinal tumorigenesis, we challenged
Tp53DIEC mice repetitively with the carcinogen azoxymethane94 Cancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc.(AOM). AOM is known to induce mutations in exon 3 of Ctnnb,
which causes constitutive activation of the Wnt pathway by
stabilizing b-catenin (Greten et al., 2004). When mice were
analyzed 16 weeks after the first AOM administration, colonic
tumor incidence was markedly increased in Tp53DIEC mice
compared to Tp53-proficient littermate controls (Figures 1A,
1E, and 1F). However, loss of p53 affected tumor incidence
but not tumor size (Figure 1B). Accordingly, proliferation index
and apoptotic index were not significantly different in tumors
between these genotypes (Figures 1C and 1D). Tumors of
both genotypes had a classical tubular morphology, whereas
some Tp53-deficient tumors were less differentiated (Figures
1G, 1H, and 1J). Whereas tumors in wild-type animals were
exclusively located in the distal colon, 18% of Tp53DIEC mice
also developed small intestinal tumors in addition to the colonic
tumors. Most importantly, at 16 weeks in all Tp53DIEC mice,
more than 50% of the colonic tumors had invaded into the
submucosa (Figures 1I and 1J). In contrast, invasive tumors
were never detected in control animals at this or even later
time points. When we monitored AOM-injected Tp53DIEC mice
for more than 20 weeks, invasion had progressed through all
intestinal layers and tumor expansion could even be observed
along the outer intestinal wall (Figure 1J). Moreover, 7 out 23
Tp53DIEC mice (30%) had developed lymph node metastases
expressing nuclear b-catenin by 24 weeks (Figures 1K and 1L),
yet no metastases could be detected in other organs such as
lung or liver.
Elimination of Early AOM-Initiated IECs Is Impaired
in Tp53DIEC Mice
AOM is considered to induce a p53-dependent apoptotic wave
in IECs within the first hours after administration (Toft et al.,
1999). Thus, we reasoned that loss of p53 in IECs may suppress
this initial apoptotic response, thereby preventing loss of initi-
ated epithelia that would subsequently increase tumor incidence
(Greten et al., 2004; Qiu et al., 2009). Indeed, IEC-restricted
p53 deficiency prevented the initial AOM-induced epithelial
apoptosis (Figures 2A–2C) and led to a substantially increased
number of phospho-H2A.X-positive colonic IECs (Figures 2D
and 2E). This was associated with the decreased expression
of genes encoding the proapoptotic proteins Bax, Puma,
Noxa, and Trail as well as Mgmt (Figure 2F), which is mainly
responsible for the repair of O6-methylguanine-containing DNA
adducts, suggesting that p53 controls both apoptosis and
DNA repair in colonic IECs after exposure to AOM. Furthermore,
the lack of apoptosis and thus the increased survival of DNA-
damaged IECs supported the notion that the diminished elimi-
nation of mutagenized IECs accounts for the elevated tumor
incidence observed in Tp53DIEC mice. To confirm this, we
crossed Tp53F/F mice to villin-creERT2 mice (el Marjou et al.,
2004) and compared tumor incidence as well as extent of inva-
sion in villin-creERT2;Tp53F/F receiving tamoxifen before or after
challenge with AOM (Figure 2G). As hypothesized, deletion of
Tp53 before AOM administration led to a significantly higher
tumor incidence (Figures 2H and 2I) but did not affect tumor
size, thus mimicking the situation observed in Tp53DIEC mice
with constitutive Cre-recombinase expression. Importantly,
however, the extent of invasion was independent of the timing
of Tp53 loss (Figure 2J), indicating that in AOM-induced
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Figure 1. Increased Tumor Incidence and Invasion in Tp53DIEC Mice
after AOM Treatment
(A) Tumor incidence in Tp53F/F and Tp53DIEC mice 16 weeks after the first of six
weekly AOM injections. Data are mean ± SE; nR 7; **p < 0.001 by t test.
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p53 Suppresses Colonic Tumor Progressiontumorigenesis, p53 controls tumor incidence and invasion via
two distinct mechanisms.
Invasion in Tp53-Deficient AOM-Initiated Tumors Is
Associated with Upregulation of Genes Involved in
Inflammation and Epithelial-Mesenchymal Transition
Although p53 is involved in the maintenance of chromosomal
stability (Levine and Oren, 2009), invasive tumors in AOM-
induced Tp53DIEC mice had only a few chromosomal aberrations
and thus were not associated with chromosomal instability
(Figure S2). To further elucidate the mechanisms that allowed
invasion of AOM-induced tumors in Tp53DIEC mice, we isolated
RNA from wild-type and Tp53-deficient tumors at 16 weeks
and performed a microarray analysis. A total of 370 genes was
significantly differentially expressed, of which 223 were up-
regulated and 147 were downregulated by at least 2-fold in
Tp53-deficient tumors compared with wild-type adenomas.
Interestingly, the largest group of upregulated genes was asso-
ciated with chemotaxis, prostaglandin synthesis, and inflam-
mation (Figure 3A) including but not restricted to Cxcl1, Cxcl2,
Cxcl10, Ccl2, Ccl11, Ccl21, Ptgs2, Lifr, and Il11, which was
confirmed by real-time PCR (Figure 3B). The second-largest
set of upregulated genes in Tp53-deficient tumors was associ-
ated with cell adhesion and morphogenesis and included genes
coding for Twist, versican, tenascin C, and fibronectin 1, well-
known regulators of metastasis and epithelial-mesenchymal
transition (EMT), a key process for invasion and metastasis of
solid tumors (Polyak and Weinberg, 2009). In accordance with
the occurrence of EMT, E-cadherin mRNA level was downregu-
lated (Figure 3C). Another prerequisite for tumor invasion is the
activation and release of stromal cell-derived proteases such
as cathepsins and matrix metalloproteases (Joyce and Pollard,
2009). Indeed, expression of Ctsl1, Mmp2, Mmp3, Mmp10,
and Mmp13 was elevated in tumors of Tp53DIEC mice, whereas
Ctsb, Ctss, and Mmp9 levels were comparable to wild-type
tumors (Figure 3D).
Enrichment of NF-kB Target Genes in p53-Deficient
Tumors
Because several of the genes we found upregulated in p53-
deficient tumors, including Cxcl1, Cxcl10, Ctsl1, Twist, and(B) Histogram showing size distribution of tumors.
(C) BrdU proliferation index of epithelial tumor cells in AOM-induced tumors in
Tp53F/F and Tp53DIEC mice. Data are mean ± SE; n R 10 tumors of each
genotype. n.s., not significant.
(D) Number of cleaved caspase-3-positive epithelial tumor cells in AOM-
induced tumors in Tp53F/F and Tp53DIEC mice. Data are mean ± SE; n R 10
tumors of each genotype.
(E–H) Hematoxylin and eosin (H&E)-stained sections of colons from mice at
16 weeks after the first AOM injection, showing representative tumor
morphology in Tp53F/F (E and G) and Tp53DIEC mice (F and H). Scale bars
represent 1,000 mm (E and F) and 50 mm (G and H).
(I and J) H&E-stained section showing representative invasive colon carci-
noma in AOM-challenged Tp53DIEC mice. A larger magnification of the boxed
area in (I) is depicted in (J). Scale bars represent 1,000 mm (I) and 100 mm (J).
(K and L) Immunohistochemical analysis of b-catenin in a lymph node
metastasis occurring in AOM-challenged Tp53DIEC mice. A larger magnifica-
tion of the boxed area in (K) is depicted in (L). Scale bars represent 500 mm
(K) and 50 mm (L).
See also Figure S1.
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Figure 2. Impaired Apoptosis and Increased DNA Damage after
AOM Application
(A) Number of cleaved caspase-3-positive colonic IECs 8 hr after AOM injec-
tion in Tp53F/F and Tp53DIEC mice. Data are mean ± SE of 50 well-oriented
crypts in two animals of each genotype; ***p < 0.0001 by t test.
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96 Cancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc.Tnc, are well-established NF-kB target genes and are overex-
pressed in cells at the invasion front compared to cells in the
center of the same tumor (Horst et al., 2009), we performed
cross-species gene set enrichment analysis (GSEA) to compare
our data set with genes that are differentially expressed in human
colon cancer cells along the invasion front. Indeed, GSEA
showed a strong correlation with and a high enrichment of this
particular set of NF-kB target genes in p53-deficient cancers,
but not in noninvasive wild-type adenomas (Figure 4A), that
were paralleled by marked phosphorylation of IkBa and RelA/
p65 (Figure 4B). Phosphorylated RelA/p65 was detectable both
in tumor epithelia as well as in the surrounding stromal cells (Fig-
ure 4C). Furthermore, CXCL1, whose human gene is one of the
most upregulated in human invading tumor cells (Horst et al.,
2009), was also strongly expressed in murine tumor epithelia
along the invasion front (Figure 4D). CXCL1, CXCL2, and CCL2
are potent chemoattractants of myeloid cells, and have therefore
been suggested to play an important role during tumor develop-
ment (Murdoch et al., 2008). Indeed, F4/80+ and Gr1+ myeloid
cells were localized particularly around the basal membrane
along the invasion front of tumors (Figures 4E and 4F). In con-
trast, these cells were less abundant andmore evenly distributed
in noninvasive wild-type adenomas (Figure S3). Furthermore,
CD3+ T cells and B220+ B cells were found only infrequently
at the invasion front (data not shown). Marked upregulation of
Twist was confirmed by immunoblot analysis in p53-deficient
cancers (Figure 4G) and could be detected in spindle-like-
shaped adenomatous cells (Figure 4H). In agreement with EMT
induction, expression of vimentin could be observed in p53-
deficient E-cadherin+ epithelial cells (Figure 4I) but not in p53-
proficient adenomatous epithelia (data not shown). Collectively,
these data indicate that during AOM-induced carcinogenesis,
IEC-specific loss of Tp53 leads to a myeloid cell-dominated
inflammatory microenvironment associated with NF-kB activa-
tion facilitating EMT and invasion.
To test whether NF-kB activation was associated with loss of
p53 function and myeloid cell recruitment in human colon
cancer, we examined surgically resected invasive colon cancer
specimens from 59 patients. Immunohistochemical analysis
showed a positive correlation between phosphorylated, acti-
vated p65 and p53 overexpression, which serves as a marker
for the presence of p53 mutations (Figures 4J–4N). Importantly,(B–E) Representative TUNEL staining (B and C) and immunohistochemical
analysis of gH2A.X (D and E) in colons of Tp53F/F and Tp53DIEC mice 8 hr after
AOM injection. Scale bars represent 50 mm.
(F) RelativemRNA levels in colonic IECs of Tp53F/F and Tp53DIECmice 8 hr after
AOM injection. mRNA levels represent the mean ± SE of a minimum of two
animals of each genotype.
(G) Schematic representation of the order of AOM and tamoxifen (TAM)
application in inducible villin-creERT2;Tp53F/F mice. 4-OHT, 4-hydrox-
ytamoxifen.
(H) Tumor incidence in villin-creERT2;Tp53F/Fmice 16weeks after the first of six
weekly AOM injections that had received AOM before (AOM/TAM) or after
tamoxifen (TAM/AOM). Data are mean ± SE; nR 3; **p < 0.001 by t test. Note
that tumor incidence in AOM/TAM-treated villin-creERT2;Tp53F/F mice was
comparable to equally treated wild-type mice (data not shown).
(I) Histogram showing size distribution of tumors.
(J) Average invasive area in colonic tumors of villin-creERT2;Tp53F/F mice that
had received AOM before (AOM/TAM) or after tamoxifen (TAM/AOM). Data are
mean ± SE; nR 3. n.s., not significant.
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Figure 3. Development of an Inflammatory Microenvironment and EMT in p53-Deficient Invasive Carcinoma
(A) Graph displays the percentage of genes that were at least 2-fold upregulated in invasive cancers from Tp53DIECmice compared to noninvasive adenomas from
Tp53F/F mice 16 weeks after the first AOM administration. Genes were sorted by their membership in KEGG pathways. Note that the group ‘‘inflammation’’
contains genes involved in chemotaxis, inflammation, and prostaglandin synthesis.
(B–D) Relative expression levels of indicated mRNAs isolated from AOM-induced tumor tissues of Tp53F/F and Tp53DIEC mice and analyzed by real-time PCR.
Data are mean ± SE; nR 3.
See also Figure S2.
Cancer Cell
p53 Suppresses Colonic Tumor Progressiontumors expressing activated p65 and overexpressing p53
were also characterized by a significant upregulation of the
macrophage-specific surface marker CD68 (Figures 4P–4R).
In contrast, expression of the neutrophil-specific marker myelo-
peroxidase was indifferent among various groups (data not
shown). Moreover, activation of NF-kB also correlated with the
occurrence of lymph node metastases in this patient cohort
(Figure 4O). Thus, our findings in cancers from AOM-initiated
Tp53DIEC mice closely recapitulate the situation in human colon
cancer.
Intestinal Barrier Function Is Impaired in AOM-
Challenged Tp53DIEC Mice
To examine whether loss of p53 in IECs led to elevated NF-kB
activation in a cell-autonomous manner, we injected Tp53DIEC
mice with lipopolysaccharide (LPS), a potent inducer of NF-kB
in IECs (Egan et al., 2004). However, neither basal nor LPS-
induced NF-kB DNA binding was elevated in the mucosa of
Tp53DIEC mice (Figures S4A–S4C). Moreover, expression of
well-established NF-kB target genes in p53-deficient IECs was
comparable to littermate controls in unchallenged mice as well
as in response to LPS (Figure S4D). Furthermore, we did notdetect increased interaction of p300/CBP andNF-kB or elevated
levels of Glut3, which were both shown to be responsible for
enhanced NF-kB activity in p53-deficient cells (data not shown)
(Kawauchi et al., 2008; Webster and Perkins, 1999). Collectively,
these results suggested a potential cell-nonautonomous regu-
lation of NF-kB in AOM-initiated Tp53DIEC mice. Increased
tight-junction permeability and decreased epithelial barrier
function have been shown to associate with human and carcin-
ogen-induced rodent colon carcinogenesis (Soler et al., 1999).
Therefore, we examinedwhether loss of IEC p53 affected epithe-
lial barrier function. Although we could not detect significant
differences in unchallenged mice (data not shown), LPS plasma
levels in AOM-initiated tumor-bearing Tp53DIEC mice were
about 2.5-fold higher than in control animals (Figure 5A). In line
with defective tight-junction permeability in AOM-challenged
animals, fluorescence in situ hybridization (FISH) revealed
enhanced translocation of intestinal bacteria into tumors
(Figures 5B and 5C). In p53-deficient cancers, occludin level
was reduced and showed a more cytoplasmic localization
compared to wild-type tumors (Figures 5D and 5E). Furthermore,
expression of genes coding for several tight-junction com-
ponents was affected in p53-deficient cancers (Figure 5F). InCancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc. 97
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Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma
(A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from
microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001.
(B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks
after the first AOM administration.
(C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed
white lines mark the basal membrane. Scale bars represent 50 mm.
(G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks
after the first AOM administration.
(H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm.
(I) Colocalization of E-cadherin (green) and vimentin (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained
using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm.
(J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm.
(N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05).
(O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02).
(P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not
(other; n = 30). Data are mean ± SE; *p < 0.05 by t test.
(Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and
phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm.
See also Figure S3.
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p53 Suppresses Colonic Tumor Progressionparticular, elevated levels of claudin 1 and Muc 1 as well as
decreased levels of claudin 2 and JAM-A have also been associ-
atedwith human colorectal cancer (Jang et al., 2002;Wang et al.,
2011). To examine whether this barrier defect preceded invasive
growth and could therefore be responsible for the creation of the
inflammatory microenvironment in p53-deficient tumors, we
orally gavaged mice with FITC-labeled dextran 4 weeks after98 Cancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc.the last AOM injection, a time point long before invasive tumors
are detectable. Even at this early stage, Tp53DIEC mice were
characterized by markedly elevated intestinal permeability and
plasma LPS levels (Figure 5G and data not shown), which coin-
cidedwith enhanced NF-kB activation in themucosa of Tp53DIEC
mice (Figures 5H–5J), suggesting that differences in NF-kB
signaling were caused by the defective epithelial barrier function
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Figure 5. Intestinal Barrier Defect in AOM-Challenged Tp53DIEC Mice
(A) Endotoxin levels in plasma collected from portal veins of Tp53F/F and Tp53DIEC mice with AOM-induced tumors. Data are mean ± SE; nR 3; **p < 0.001 by
t test. EU, endotoxin unit.
(B and C) FISH using a FITC-labeled universal eubacteria probe (EUB 338). Scale bars represent 20 mm.
(D and E) Immunofluorescent analysis of occludin in noninvasive adenomas from Tp53F/F mice (D) and invasive cancers from Tp53DIEC mice (E) 16 weeks after the
first AOM administration. Scale bars represent 20 mm.
(F) Relative levels of mRNAs isolated from AOM-induced tumor tissues of Tp53F/F and Tp53DIEC mice and analyzed by real-time PCR. Data are mean ± SE; nR 3.
(G) FITC-dextran plasma levels 4 hr after oral gavage in unchallenged or AOM-injected Tp53F/F and Tp53DIEC mice 4 weeks after the last AOM challenge. Data are
mean ± SE; n = 8; *p < 0.05 by t test.
(H) Electrophoretic mobility shift assay (EMSA) and immunoblot analysis (WB) for the indicated proteins in lysates of colonic mucosa from Tp53DIEC and Tp53F/F
mice 4 weeks after the last AOM challenge.
(I and J) Immunohistochemical analysis of p-p65 in colonic mucosa of Tp53DIEC and Tp53F/F mice 4 weeks after the last AOM challenge. Scale bars represent
20 mm.
(K) Schematic representation of the AOM and antibiotic administration. Two weeks after the completion of six weekly AOM injections, animals received
a combination of vancomycin, metronidazole, ampicillin, and neomycin (Abx) in their drinking water for an additional 2 weeks prior to sacrifice.
(L) EMSA and immunoblot analysis for the indicated proteins in lysates of colonic mucosa from untreated (untr.) or antibiotic-treated (Abx) Tp53DIEC mice 4 weeks
after the last AOM challenge.
(M and N) Immunohistochemical analysis of p-p65 in colonic mucosa of untreated (M) or antibiotic-treated (N) Tp53DIEC mice 4 weeks after the last AOM
challenge. Scale bars represent 50 mm.
(O) Relative expression levels of mRNAs isolated from colonic mucosa of untreated or antibiotic-treated Tp53F/F and Tp53DIEC mice 4 weeks after the last AOM
challenge and analyzed by real-time PCR. Data are mean ± SE; n = 6.
See also Figure S4.
Cancer Cell
p53 Suppresses Colonic Tumor Progressionand translocation of bacteria as well as by bacterial products
such as LPS. To confirm this hypothesis, we depleted the intes-
tinal microflora by treating AOM-initiated mice with a combina-
tion of vancomycin, metronidazole, ampicillin, and neomycinfor 2 weeks (Figure 5K). Successful depletion was confirmed
by plating stool samples on microbiological plates. Indeed, anti-
biotic treatment nearly completely abolished NF-kB activation
in carcinogen-challenged Tp53DIEC mice (Figures 5L–5N) andCancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc. 99
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Figure 6. Loss of Ikkb in IECs Reduces Invasion in Tp53DIEC Mice
(A) Schematic representation of the order of AOM and TAM application in
inducible villin-creERT2/Tp53F/F mice and villin-creERT2/Tp53F/F/IkkbF/F.
(B) Tumor incidence in Tp53DIEC;IkkbWT (black bars) and Tp53DIEC;IkkbDIEC
(gray bars) mice 18 weeks after tamoxifen administration. Data are mean ± SE;
n = 9 animals/genotype. n.s., not significant.
(C) BrdU proliferation index of epithelial cancer cells in AOM-induced tumors in
Tp53DIEC;IkkbWT (black bars) and Tp53DIEC;IkkbDIEC (gray bars) mice. Data are
mean ± SE; nR 5 tumors of each genotype.
(D) Number of cleaved caspase-3-positive epithelial cancer cells in AOM-
induced tumors in Tp53DIEC;IkkbWT (black bars) and Tp53DIEC;IkkbDIEC (gray
bars) mice. Data are mean ± SE; nR 5 tumors of each genotype.
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Ptgs2 (Figure 5O). Collectively, these results suggest that in
AOM-initiated IECs, loss of p53 alters the composition of tight
junctions, causing an impaired barrier function and subsequently
elevated circulating plasma LPS levels, which culminates in
NF-kB activation and chemokine upregulation.
Loss of IKKb-Dependent NF-kB Activation in IECs
or Myeloid Cells Reduces Invasion and Metastasis
To confirm that NF-kB signaling functionally contributes to colon
cancer progression, we examined IEC- or myeloid cell-restricted
loss of IKKb in Tp53DIEC mice. In order to specifically address
IEC-specific IKKb/NF-kB activation during the invasion stage
rather than the carcinogen-induced initiation stage, we crossed
IkkbF/F mice to villin-creERT2;Tp53F/F mice. Simultaneous dele-
tion of Ikkb and Tp53 in IECs was achieved by oral tamoxifen
application after completion of AOM injections (Figure 6A), to
exclude potential interference of AOM-triggered apoptosis and
DNA-damage repair by loss of NF-kB activation in epithelial
cells. Whereas IEC-restricted absence of Ikkb did not affect
tumor incidence, proliferation, or apoptosis (Figures 6B–6D), it
markedly reduced the occurrence of invasive tumors. Only five
out of nine IkkbDIEC;Tp53DIEC mice developed invasive lesions
at all, and in these animals only 10% of tumors had invaded
into the submucosa, in contrast to Ikkb wild-type-expressing
Tp53DIEC mice, in which about 30% of tumors progressed in all
animals analyzed (Figures 6E and 6F). In agreement with NF-
kB’s suggested role in this model and a marked decrease in
the phosphorylation of IkBa and p65, CXCL1 expression (Figures
6G and 6H), accumulation of F4/80+ and Gr1+ myeloid cells
(Figures 6I–6L), as well as Twist expression (Figure 6M) were
reduced in IkkbDIEC;Tp53DIEC mice, whereas E-cadherin expres-
sion was conversely elevated (Figure 6M). These data supported
the notion that NF-kB in IECs is indeed required for induction
of EMT and myeloid cell recruitment.
To examine the contribution of myeloid cell-dependent NF-kB
signaling to invasion and metastasis of p53-deficient carci-
nomas, we used LysM-Cre;IkkbF/F (IkkbDmye) mice. We could
not directly crossbreed Tp53DIEC to IkkbDmye mice because this
would have resulted in simultaneous deletion of p53 and IKKb
in both IECs and myeloid cells. Therefore, we reconstituted
lethally irradiated Tp53DIEC mice with bone marrow from IkkbF/F
or IkkbDmye animals before the AOM challenge and monitored
tumor progression (Figure 7A). Transplantation of IkkbDmye
bone marrow did not affect tumor incidence or the overall
frequency of invasive carcinomas in Tp53DIEC mice (Figures 7B
and 7C). However, specifically along the invasion front, which
is the location where most of the macrophages and neutrophil(E and F) Incidence of invasive cancers in Tp53DIEC;IkkbWT (black bars)
and Tp53DIEC;IkkbDIEC (gray bars) mice. Data are mean ± SE; n = 9 animals/
genotype; **p < 0.001 by t test.
(G–L) Immunohistochemical analysis of CXCL1 (G and H), F4/80 (I and J), and
Gr-1 (K and L) in invasive cancers in Tp53DIEC;IkkbWT (G, I, and K) and
Tp53DIEC;IkkbDIEC (H, J, and L) mice. Note that CXCL1 is still expressed in
tumor-infiltrating leukocytes, whereas it is absent in IECs of Tp53DIEC;IkkbDIEC
mice. Scale bars represent 50 mm.
(M) Immunoblot analysis for the indicated proteins in lysates from invasive
cancers from Tp53DIEC;IkkbWT and Tp53DIEC;IkkbDIEC mice 18 weeks after the
first AOM administration.
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p53 Suppresses Colonic Tumor Progressioncells are recruited to, myeloid-specific Ikkb deficiency markedly
decreased proliferation of IECs, elevated the number of
apoptotic IECs, and consequently decreased the extent of inva-
sion (Figures 7D–7F, 7H, and 7I). Moreover, whereas metastatic
spread could be observed in 30% of Tp53DIEC mice adoptively
transferred with control IkkbF/F bonemarrow, not a single metas-
tasis was found when bone marrow from IkkbDmye mice was
transplanted (Figure 7G). Recruitment of F4/80+ and Gr1+ cells
to the invasion front was not affected (data not shown), indicating
that downregulation of NF-kB-dependent proinflammatory cyto-
kines that could act in a paracrine manner was responsible for
differences in proliferation and survival of invading tumor
epithelia. Indeed, expression of mRNA encoding various cyto-
kines, chemokines, and matrix metalloproteases was markedly
downregulated (Figures 7J and 7K). We previously demon-
strated in a model of colitis-associated tumorigenesis that
gp130-dependent STAT3 activation rather than NF-kB signaling
controls proliferation of AOM-mutagenized IECs (Bollrath et al.,
2009; Greten et al., 2004). Similarly, and in line with decreased
levels of the gp130/STAT3-activating cytokine IL-11, we ob-
served a marked downregulation of tyrosine-phosphorylated
STAT3 in invading Tp53DIEC tumor epithelia when transplanted
with bone marrow from IkkbDmye mice, whereas phosphorylation
of IkBawas only moderately affected (Figures 7L–7O). Indeed, in
Tp53DIEC mice, strong nuclear accumulation of phosphorylated
Stat3 was detected along the invasion front compared to
noninvasive AOM-induced adenomas in wild-type mice, and
this was even more pronounced in metastatic cells (Figure S5),
suggesting that paracrine NF-kB-dependent activation of
Stat3 is involved in the proliferation, survival, and metastatic
spread of p53-deficient tumor cells. Importantly, in colon cancer
patients, the degree of invasion and the occurrence of lymphatic
metastases correlate with activation of STAT3 (Kusaba et al.,
2005). Collectively, our results strongly support a key causal
role of epithelial andmyeloid IKKb/NF-kB activation in the gener-
ation of an inflammatory microenvironment and the occurrence
of EMT triggered by p53 deficiency leading to colonic tumor
invasion and lymph node metastasis.
Tp53DIECMice Comprise a SuitableModel for Preclinical
Studies
Because AOM-initiated tumors develop in the distal colon, they
can be easily monitored by a mini endoscopy system (Figures
8A and 8B) (Becker et al., 2006). Thus, we reasoned that
Tp53DIEC mice might represent an excellent model for longitu-
dinal preclinical therapeutic and endoscopic studies, consid-
ering that AOM-induced tumors range from the early noninvasive
stage to fully metastasized invasive cancer. Miniprobe-based
confocal laser scanning microscopy (CLSM) in combination
with the intravenous application of fluorescein allows the evalu-
ation of blood vessel length and area in vivo (Waldner et al., 2011)
and has been successfully applied in human patients for the
detection of endoscopically invisible neoplasia in Barrett’s
esophagus as well as for the diagnosis of biliary neoplasia
(Meining et al., 2008; Pohl et al., 2008). To examine whether
we could apply this method to monitor potential changes in
vascularization during the carcinogenic process in p53-deficient
tumors, we performed miniprobe-based CLSM in AOM-treated
Tp53DIEC mice at early and late tumor stages. In agreementwith the induction of an angiogenic switch (Bergers and
Benjamin, 2003), a significant increase of blood vessel length
and blood vessel area from early- to late-stage carcinogenesis
could be detected by CLSM (Figures 8C–8F). This increase
was confirmed by immunohistochemical staining of VE-cadherin
in Tp53DIEC tumors at 10 and 18 weeks after the first AOM
injection, representing an early noninvasive as well as a late
invasive stage of carcinogenesis (Figure 8G). Accordingly,
Tp53-deficient cancers were characterized by a marked devel-
opment of hypoxia (Figures 8H–8J), one of the prerequisites for
the induction of an angiogenic switch (Bergers and Benjamin,
2003).We then assessedwhetherminiprobe-basedCLSMcould
be applied for monitoring antiangiogenic therapy. Indeed, CLSM
detected a significant decrease in vessel length and area upon
treatment with the antiangiogenic receptor tyrosine kinase inhib-
itor sunitinib (Figures 8L and 8M), providing further evidence for
the suitability of Tp53DIEC mice in preclinical studies.
DISCUSSION
TP53 is one of the most frequently mutated genes in human
cancers, and loss of p53 is a late event in colorectal carcinogen-
esis and is associated with invasive growth (Fearon and Vogel-
stein, 1990; Levine and Oren, 2009). Although p53 deficiency
in IECs is not sufficient to initiate spontaneous intestinal tumor
development, 100% of Tp53DIEC mice develop invasive cancer
once challenged with a carcinogen that activates the Wnt
pathway. Importantly, our results imply a context-dependent
function of p53 during the intestinal carcinogenic process.
During the initiation phase of the AOM model, p53 controls
IEC survival and DNA repair, in agreement with its established
role in response to genotoxic stress (Meek, 2009). However, in
late-stage human adenomas, suppression of apoptosis does
not correlate with loss of p53 (Fazeli et al., 1997). Based on
our findings, we suggest that p53 suppresses an inflammatory
microenvironment associated with the activation of NF-kB,
which facilitates induction of EMT, during the progression stage.
We provide evidence that NF-kB activation is indirectly triggered
by elevated levels of circulating plasma LPS, a consequence of
impaired intestinal epithelial barrier function in response to
carcinogen exposure. Although attenuated tight-junction integ-
rity can also be observed in p53 wild-type tumors, loss of p53
function seems to aggravate it. Whereas in respect to human
cancers, one has to carefully consider that p53 function is
presumably lost initially in only a few cells—in contrast to our
mice that lack p53 in the entire colonic epithelium—it is impor-
tant to note that the transition from adenoma to invasive cancer
is also associated with an increased barrier defect in human
disease (Soler et al., 1999). The particular indirect interaction
between p53 and NF-kB shown here may be unique to colo-
rectal carcinogenesis and may explain contrasting results
regarding p53 function in other malignancies such as murine
lymphoma, where p53 function is dispensable for lymphoma-
genesis in response to irradiation-triggered acute DNA damage
(Christophorou et al., 2006). However, our results underscore
the relevance of intestinal microorganisms for colon cancer
progression, a notion that has been emerging over the last
years for several inflammatory and malignant diseases (Hill
and Artis, 2010).Cancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc. 101
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Figure 7. Loss of Ikkb in Myeloid Cells Suppresses Proliferation and Metastatic Spread of Invading Cancer Cells
(A) Schematic representation of the model. Tp53DIEC animals were lethally irradiated and transplanted with bone marrow from IkkbF/F or IkkbDmye mice. Eight
weeks later, AOM was injected once weekly for six weeks. Mice were analyzed 10–13 weeks after the first AOM administration.
(B) Tumor incidence in AOM-injected Tp53DIEC mice transplanted with bone marrow from IkkbF/F (black bars) or IkkbDmye (gray bars) mice. Data are mean ± SE;
n = 11 animals/genotype. n.s., not significant.
(C) Incidence of invasive cancers in AOM-injected Tp53DIEC mice transplanted with bone marrow from IkkbF/F (black bars) or IkkbDmye (gray bars) mice. Data are
mean ± SE; n = 11 animals/genotype.
(legend continued on next page)
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Cancer Cell
p53 Suppresses Colonic Tumor ProgressionOur findings demonstrate that IKKb/NF-kB can have distinct
functions during different phases of colonic tumor development.
During colitis-associated tumorigenesis in p53-proficient mice,
NF-kB is mainly responsible for transcriptional upregulation of
antiapoptotic genes during the promotion stage. However, in
the absence of p53, NF-kB activation induces Twist expression,
thereby allowing EMT induction, which presumably is a pre-
requisite for the invasion of AOM-mutagenized colonocytes.
Furthermore, recruitment of myeloid cells and their release
of NF-kB-dependent proinflammatory cytokines enforce a
feedforward loop and activate STAT3 in invading cancer cells
to stimulate their proliferation, survival, and metastatic spread.
Our data contrast with previous findings in ApcMin/+ mice,
where p53 deficiency did not affect tumor incidence or pro-
gression (Clarke et al., 1995; Fazeli et al., 1997). One possible
explanation might be that other malignancies developed in the
complete absence of p53, which may have affected intestinal
tumor progression or shortened the life span of themice. Another
possibility is that mice on mixed genetic backgrounds were
used in those previous studies. Accordingly, when mice on a
pure genetic background were studied, p53-deficient ApcMin/+
mice showed a tendency toward enhanced tumor progression
and the development of invasive cancer (Halberg et al., 2000).
Recently, it was suggested that p53 controls a specific gene
signature to suppress intestinal tumor progression in aCsnk1a1-
deficient background (Elyada et al., 2011). However, we did not
detect enrichment of these genes in AOM-initiated cancers (data
not shown). Presumably, tumor location (small intestine versus
colon) and/or mode of Wnt activation (Csnk1a1 ablation versus
stabilizing Ctnnb1 mutations) account for this difference. Only
very few mouse models of intestinal tumorigenesis develop
invasive colon cancer and metastasize. To date, it remains
unclear which pathways are essential specifically for colonic
tumor progression in mice. Concomitant activation of oncogenic
K-ras and conditional loss of Apc led to submucosal invasion
and liver metastases in about 20% of these mice (Hung et al.,
2010). However, AOM-induced carcinomas in Tp53DIEC mice
did not harbor any K-ras mutations (data not shown). Further-
more, oncogenic K-ras activation in IECs does not promote
invasion in the AOM model (Bennecke et al., 2010). Our data
strongly support that loss of p53 and the associated NF-kB
activation culminating in EMT could be among the essential
events that regulate colonic tumor progression.(D and E) Index of BrdU-positive cells (D) and cleaved caspase-3-positive cells (E)
with bone marrow from IkkbF/F (black bars) or IkkbDmye (gray bars) mice. Data are
(F) Total invasive area/animal in cancers in AOM-injected Tp53DIECmice transplant
are mean ± SE; n = 11 animals/genotype.
(G) Incidence of invasive cancers in AOM-injected Tp53DIEC mice transplanted w
(H and I) Representative H&E-stained sections of colons from AOM-injected Tp5
IkkbDmye (IkkbDmye>Tp53DIEC) mice. Scale bars represent 200 mm.
(J and K) Relative expression levels of mRNAs isolated from AOM-induced tumo
bars) or IkkbDmye (gray bars) mice and analyzed by real-time PCR. Data are mea
(L) Immunoblot analysis for the indicated proteins in lysates from invasive cance
mice.
(M) Average number of p-STAT3-positive cells/invading tumor epithelial cells in A
bars) or IkkbDmye (gray bars) mice. Data are mean ± SE; nR 4 animals/genotype
(N and O) Immunohistochemical analysis of p-STAT3 in invasive cancers of AOM
IkkbDmye (O) mice. Scale bars represent 50 mm.
See also Figure S5.Interestingly, AOM-challenged Tp53DIEC mice developed only
lymph node metastases. Here, we provide evidence that NF-kB
activation in colon tumors is also associated with the presence of
lymph nodemetastasis in human patients. Similarly, overexpres-
sion of the two well-described NF-kB target gene products
CXCL1 and Twist correlates with nodal invasion in colon cancer
patients (Ogata et al., 2010; Valde´s-Mora et al., 2009), further
underlining the relevance of Tp53DIEC mice for human disease.
One goal of generating an autochthonous immune-competent
mouse model that faithfully recapitulates the histopathology and
genetic alterations of specific human cancer is to functionally
investigate the biological basis of tumor development. Another
important aim of such an effort is to create an animal model
that can be used in translational preclinical studies. Our model
presented here achieves both aims. Morphological appearance
of p53-deficient tumors and their gene signature reveals high
resemblance to invasive human colon cancer. Thus, AOM-initi-
ated Tp53DIEC mice comprise a well-suited model to dissect
the importance of the different inflammatory signaling pathways
in the various cellular compartments of the tumor microenviron-
ment to further understand themolecular mechanisms leading to
metastasis. Furthermore, tumor location and the possibility of
endoscopic monitoringmake thismodel suitable for translational
diagnostic and therapeutic studies.
EXPERIMENTAL PROCEDURES
Mice
To delete exons 2–10 of Tp53 in IECs, we crossed floxed Tp53 (Jonkers et al.,
2001) obtained from the National Cancer Institute to villin-Cre (Madison et al.,
2002) or villin-CreERT2 (el Marjou et al., 2004) mice. IkkbF/F and IkkbDmye have
been described previously (Greten et al., 2004). All mice including littermate
controls were crossed on an FVB background for at least four generations,
and in all experiments littermate controls were used. In villin-CreERT2 mice,
deletion was induced by five daily oral administrations of 1 mg tamoxifen
(Sigma) in an ethanol/oil mixture. In adoptive transfer experiments, Tp53DIEC
mice were irradiated (9 Gy) and 2 3 106 bone marrow cells from IkkbF/F or
IkkbDmye mice were transferred by tail vein injection. Eight weeks after
transplantation, AOM injections commenced. Azoxymethane (Sigma) was
injected intraperitoneally (i.p.) once a week for 6 weeks at 10 mg/kg. Sunitinib
(40 mg/kg) was applied daily by oral gavage for 14 days. Mini endoscopy was
performed on anesthetized mice using a mouse mini endoscopy system (Karl
Storz). A confocal miniprobe (Mauna Kea Technologies) was applied via the
working channel of the endoscope, and video sequences (each 20 s, 12
frames/s) were recorded within 10 min after intravenous injection of 100 ml
fluorescein (1%). Vessel length and area of a minimum of ten images peralong the invasion front of cancers in AOM-injected Tp53DIEC mice transplanted
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edwith bonemarrow from IkkbF/F (black bars) or IkkbDmye (gray bars) mice. Data
ith bone marrow from IkkbF/F (black bars) or IkkbDmye (gray bars) mice.
3DIEC mice transplanted with bone marrow from IkkbF/F (IkkbF/F>Tp53DIEC) or
r tissues of Tp53DIEC mice transplanted with bone marrow from IkkbF/F (black
n ± SE; n = 2/genotype.
rs from Tp53DIEC mice transplanted with bone marrow from IkkbF/F or IkkbDmye
OM-injected Tp53DIEC mice transplanted with bone marrow from IkkbF/F (black
; **p < 0.001 by t test.
-challenged Tp53DIEC mice transplanted with bone marrow from IkkbF/F (N) or
Cancer Cell 23, 93–106, January 14, 2013 ª2013 Elsevier Inc. 103
normal mucosa invasive carcinoma
40 μm100 μm
C
LS
M
en
do
sc
op
y
A B
C D
10
15
20
25
30
essev
aera l
(1
x1
04
 μ
m
2 )
untr. aden. inv. ca.
Tp53ΔIEC
***
***
0
1
2
3
4htgnel lessev
(1
x1
04
 μ
m
)
untr. aden. inv. ca.
Tp53ΔIEC
*** *
E F
20
40
60
80
100
untr. aden. inv. ca.
Tp53ΔIEC
0
***
***G
Tp53F/F Tp53ΔIEC
H I
Hypoxyprobe Hypoxyprobe
AOM Sunitinib
CLSM CLSM
2
3
4
before before retfaretfa
essev
aera l
(1
x1
04
 μ
m
2 )htgnel lessev
(1
x1
04
 μ
m
)
Tp53ΔIECTp53ΔIEC
*** ***
K
L M
0
0.2
0.4
0.6
0.8
Tp53F/F Tp53ΔIEC
J
mµ( aera cixopyh
2 )/
a ro
mut
re
mµ( a
2 ) ** *
sev
mµ( aera les
2 )/
dleif x01
15
17
19
21
23
25
Figure 8. Increased Vascularization in p53-Deficient Carcinomas Can Be Evaluated by Endoscopically Guided Confocal Laser Scanning
Microscopy
(A–D) Representative images obtained by white-light mini endoscopy (A and B) and confocal laser scanning microscopy of fluorescein-injected animals (C and D)
in unchallenged (A and C) and AOM-initiated Tp53DIEC mice with invasive cancer (B and D).
(E and F) Quantification of blood vessel length (E) and blood vessel area (F) in untreated animals (untr.) and noninvasive (aden.) and invasive cancers (inv. ca.) in
Tp53DIEC mice by CLSM. Data are mean ± SE; nR 4. *p < 0.05, ***p < 0.0001 by t test.
(G) Quantification of blood vessel area in untreated animals and noninvasive and invasive cancers in Tp53DIEC mice. Vessels were visualized by immunohisto-
chemical staining for VE-cadherin, and the area was measured per 1003 magnification field on a Zeiss Axio Imager using AxioVision software. Data are
mean ± SE; nR 6; ***p < 0.0001 by t test.
(H and I) Immunohistochemical analysis of tissue hypoxia using Hypoxyprobe, demonstrating increased levels of hypoxia in invasive cancers from Tp53DIEC mice
(I) compared to noninvasive adenomas from Tp53F/F mice (H) 16 weeks after the first AOM administration. Scale bars represent 100 mm.
(J) Quantification of hypoxic areas normalized to tumor area in noninvasive adenomas from Tp53F/F mice and invasive cancers from Tp53DIEC mice 16 weeks
after the first AOM administration. Data are mean ± SE; nR 4; ***p < 0.0001 by t test.
(K) Schematic representation of the order of AOM and sunitinib administration and when CLSM was performed.
(L and M) Quantification of blood vessel length (L) and blood vessel area (M) by CLSM in established tumors in fluorescein-injected Tp53DIEC mice before and
after sunitinib treatment. Data are mean ± SE; nR 4; ***p < 0.0001 by t test.
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p53 Suppresses Colonic Tumor Progressiontumor were quantified using Cellvizio software. To measure intestinal barrier
permeability, noncharged FITC-dextran (MW 4000; Sigma) was prepared at
80 mg/ml in PBS. Mice were orally gavaged with 60 mg per 100 g of body
weight. After 4 hr, serum was collected and FITC-dextran was measured
using a fluorometer (BMG Labtech FLUOstar Orange) at 485 nm excitation
and 510 nm emission. Bacterial endotoxin levels were determined using an
endpoint chromogenic Limulus Amebocyte Lysate assay (Lonza) according
to the manufacturer’s instructions. To deplete intestinal microflora, mice
were treated with a combination of ampicillin (0.22 g/l), vancomycin (0.1 g/l),
neomycin (0.214 g/l), andmetronidazole (0.213 g/l) for 2 weeks. All procedures
were reviewed and approved by the Regierung von Oberbayern.
Human Samples
Human tumor samples were collected within the first 30 min after resection.
Tumors were macroscopically dissected by an experienced pathologist,
snap-frozen, and stored in liquid nitrogen (196C) until usage. Before
molecular analysis, tumor diagnosis was confirmed and tumor content (at
least 70%) was determined by hematoxylin-eosin staining. All procedures
were performed with the approval of the ethics committee of the Technical
University of Munich on samples from subjects who had given their written
informed consent.
Protein Analysis
Isolation of IECs and immunoblot analysis were performed as previously
described (Bollrath et al., 2009). The following antibodies were used in
immunoblot analysis: b-actin (Sigma; A4700), IkBa (Santa Cruz; sc-371), phos-
pho-IkBa (Cell Signaling; 9241), p65 (Santa Cruz; SC-372), phospho-p65
(Cell Signaling; 3037), E-cadherin (Becton Dickinson; 610182), and Twist
(Abcam; 49254). NF-kB binding activity was determined using an Odyssey
infrared EMSA kit (LICOR). Ten micrograms of protein sample was incubated
with 1 mM 30 DY682-labeled NF-kB consensus oligo. Samples were run on
a 5% native TBE acrylamide gel, and bands were detected on an Odyssey
infrared imaging system.
Histological Analysis
Standard immunohistochemical procedures were performed using the
following antibodies: b-catenin (Santa Cruz; sc-1496), bromodeoxyuridine
(BrdU) (AbD Serotec; MCA 2060), cleaved caspase-3 (Cell Signaling; 9661),
CXCL1 (R&DSystems;MAB453), F4/80 (Caltag; MF48000), Gr-1 (eBioscience;
12-5931-82), phospho-Histone H2A.X (Cell Signaling; 2577), E-cadherin
(Becton Dickinson; 610182), Twist (Abcam; 49254), vimentin (Santa Cruz;
SC-7557), VE-cadherin (Santa Cruz; SC-6458), and occludin (Invitrogen;
711500). For immunofluorescent detection of E-cadherin, the Vector Labs
Mouse on Mouse kit was used; vimentin and occludin were detected using
Alexa Fluor 594-labeled anti-goat antibody (Invitrogen). Alcian blue staining
was performed to detect acetic mucins and mucosubstances according to
standard procedures. Paneth cells were detected by azure-eosin staining.
For detection of apoptosis, the ApoAlert DNA Fragmentation Assay kit
(Clontech; 630108) was used according to the manufacturer’s instructions.
For the detection of tissue hypoxia, the Hypoxyprobe-1 Plus kit (Chemicon
International; HP2-100) was used according to the manufacturer’s instruc-
tions. In brief, 60 mg/kg body weight of pimonidazole hydrochloride was
injected i.p. 1 hr before sacrifice. In hypoxic tissues, reductively activated
2-nitroimidazole protein adducts were detected by the peroxidase immu-
nohistochemistry technique using FITC-conjugated mAb directed against
pimonidazole protein adducts and a secondary mouse anti-FITC mAb
conjugated to HRP. Hematoxylin was used for counterstaining.
Statistical Analysis
Data are expressed as mean ± SEM. Differences were analyzed by Student’s
t test using Prism5 (GraphPad Software). The p values % 0.05 were consid-
ered significant.
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